New discoveries in the field of geroscience could transform management strategies for cardiovascular disease in older adults, with the potential to mitigate premature aging, reduce health care disparities and improve population health spans, according to a recently published JACC Scientific Statement.

Polypharmacy is increasingly common among patients with heart failure (HF), including among those with mildly reduced (HFmrEF) and those with preserved ejection fraction (HFpEF) due to their high burden of comorbidities. Dapagliflozin effectively and safely reduces worsening HF or cardiovascular death in patients across a broad range of medication burden, according to a post hoc analysis of the DELIVER trial published in JACC: Heart Failure.

After hospitalization for heart failure (hHF), the risk of rehospitalization as well as costs was high, while the use of guideline-directed medical therapy (GDMT) during the first year after discharge did not increase, according to a study published in JACC: Heart Failure. The findings suggest the need to focus on earlier and greater use of GDMT to reduce these risks.

With the advancement of percutaneous transcatheter interventions as standard therapies for cardiovascular diseases, complication rates are lower, making same-day discharge (SDD) possible for patients, according to a state-of-the-art review published in JACC: Cardiovascular Interventions.